1-4 of 4
Ultan McDermott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Vera Grinkevitch, Mark Wappett, Nyree Crawford, Stacey Price, Andrea Lees, Christopher McCann, Katherine McAllister, Jochen Prehn, Jamie Young, Jess Bateson, Lewis Gallagher, Magali Michaut, Vivek Iyer, Aikaterini Chatzipli, Syd Barthorpe, Daniel Ciznadija, Ido Sloma, Amy Wesa, David A. Tice, Lodewyk Wessels, Mathew Garnett, Daniel B. Longley, Ultan McDermott, Simon S. McDade
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 594–606.
https://doi.org/10.1158/1535-7163.MCT-21-0532
Published: 01 April 2022
View article titled, Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Open the PDF for Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists in another window
Includes: Supplementary data
Journal Articles

Abstract P066: Gain and loss of function genome-wide CRISPR screens identify Hippo signalling as an important driver of resistance in EGFR mutant lung cancer

Matthias Pfeifer, Jonathan Brammeld, Stacey Price, Matthew Martin, Hannah Thorpe, Aurelie Bornot, Ercia Banks, Nin Guan, Shanade Dunn, Maria Lisa Guerriero, Daniel O'Neill, James Pilling, Davide Gianni, James Brownell, Paul Smith, Ultan McDermott
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P066.
https://doi.org/10.1158/1535-7163.TARG-21-P066
Published: 01 December 2021
View article titled, Abstract P066: Gain and loss of function genome-wide CRISPR screens identify Hippo signalling as an important driver of resistance in EGFR mutant lung cancer
Journal Articles

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, Meredith Williams, Yong Cheng Tan, Lai Chun Ong, Albert Cheong, Bee Kheng Ng, Chithra Amalini, Babita Madan, Harish Nagaraj, Ramesh Jayaraman, Khalid M. Pasha, Kantharaj Ethirajulu, Wee Joo Chng, Nurulhuda Mustafa, Boon Cher Goh, Cyril Benes, Ultan McDermott, Mathew Garnett, Brian Dymock, Jeanette M. Wood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (2): 151–161.
https://doi.org/10.1158/1535-7163.MCT-12-0466
Published: 10 February 2013
View article titled, VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Open the PDF for VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer in another window
Includes: Supplementary data
Journal Articles

The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan, Ultan McDermott, Jennifer Lamb, Shyamala Maheswaran, Jeffrey Settleman, Daniel A. Haber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 874–879.
https://doi.org/10.1158/1535-7163.MCT-07-2387
Published: 15 April 2008
View article titled, The T790M “gatekeeper” mutation in <em>EGFR</em> mediates resistance to low concentrations of an irreversible EGFR inhibitor
Open the PDF for The T790M “gatekeeper” mutation in <em>EGFR</em> mediates resistance to low concentrations of an irreversible EGFR inhibitor in another window